Fudan Zhangjiang Boosts Yield on Idle Cash With RMB210 Million SPD Bank Deposit
I'm LongbridgeAI, I can summarize articles.Shanghai Fudan Zhangjiang Bio Pharmaceutical Co (HK:1349) invested RMB210 million of idle funds in an 88-day principal-guaranteed structured deposit with SPD Bank. The low-risk product offers a floating annualized return of 1.00%-1.95%, linked to EUR/USD movements. Classified as a disclosable transaction under Hong Kong Listing Rules, this move reflects the company's conservative treasury management strategy to optimize returns on surplus cash while preserving capital and liquidity.
The latest update is out from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ).
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co has subscribed to a principal-guaranteed structured deposit product with SPD Bank, investing RMB210 million of idle self-owned funds generated from daily operations. The 88-day product is assessed as low-risk, offers a floating annualized return between 1.00% and 1.95%, and links its yield to EUR/USD movements, providing the company with modest income on surplus cash.
Under Hong Kong Listing Rules, the size of this investment causes one or more applicable percentage ratios to exceed 5% but remain below 25%, classifying the transaction as a disclosable transaction requiring reporting and public announcement without shareholder approval. The move underscores the company’s conservative treasury management, balancing capital preservation with enhanced returns, and signals disciplined liquidity deployment for stakeholders monitoring its financial strategy.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co operates in the biopharmaceutical industry, focusing on the research, development and commercialization of pharmaceutical products. The company uses financial instruments to manage its liquidity, allocating idle operational funds into low-risk, principal-guaranteed structured deposit products to optimize returns while preserving capital.
Its market focus includes maintaining a stable financial position to support ongoing operations and investments in drug development. By engaging in short-term, low-risk banking products, the company seeks incremental yield on surplus cash without compromising liquidity or risk management standards.
Average Trading Volume: 2,680,614
Current Market Cap: HK$772.6M
For a thorough assessment of 1349 stock, go to TipRanks’ Stock Analysis page.